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Abstract
The question of selecting the “best” amongst different choices is a common
problem in statistics. In drug development, our motivating setting, the question
becomes, for example: which treatment gives the best response rate. Motivated
by a recent development in the theory of context-dependent information measures,
we propose an experimental design based on a simple and intuitive criterion to
govern arm selection in an experiment with multinomial outcomes. The criterion
leads to reliable selection of the correct arm without any parametric or monotonic-
ity assumptions. The asymptotic properties of the design are studied for different
allocation rules and the small sample size behaviour is evaluated in simulations in
the context of Phase I and Phase II clinical trials. We compare the proposed design
to currently used alternatives and discuss its practical implementation.
Keywords: Multinomial Outcomes; Dose Finding; Experimental Design; Infor-
mation Gain; Weighted Differential Entropy
1 Introduction
Over the past decades a variety of different methods for clinical trials aiming to select the
“optimal” arm (e.g. dose, treatment, combination of treatments,...) have been proposed
in the literature (O’Quigley and others , 1990; Wages and others , 2011; Magirr and others ,
2012; Villar and others , 2015; Lee and others , 2016). Given m arms, the aims of Phase
I and Phase II clinical trials are often to identify the target arm (TA) corresponding to
the toxicity probability closest to the target 0 < γt < 1 and/or the efficacy probability
closest to the target 0 < γe < 1. Despite the similar problem formulation for Phase I
(evaluating toxicity) and Phase II (evaluating efficacy) trials, quite different approaches
are generally utilized.
In Phase I dose-escalation trials, model-based designs assuming a monotonic dose-
toxicity relationship are shown to have good operating characteristics in the setting of a
single cytotoxic drug (Iasonos and others , 2016). The ability to find the TA using these
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methods is, however, rather limited if the assumption of monotonicity is not satisfied
(Shen and O’Quigley, 1996). While this is not common for cytotoxic drugs, the uncer-
tainty about toxicity and efficacy orderings holds for drugs combinations, dose-schedules
and molecularly targeted drugs (Wages and others , 2011; Lagarde and others , 2015).
To overcome the issue of an unknown ordering in the context of Phase I trials, some
specialised approaches for combination and dose-schedule trials have been proposed (e.g.
Thall and others , 2003; Wages and others , 2011; Guo and others , 2016). The common
features of the majority of novel Phase I methods relaxing the monotonicity assumption
is either relying on a parametric model or on explicit order of toxicity/efficacy. While
such methods allow to borrow information across treatment arms, they might fail to
find the TA if the model or ordering is misspecified. There is also growing interest in
advanced trials with a large number of potential orderings where specifying all of them
(or a corresponding parametric model) is not feasible (see e.g. Mozgunov and Jaki, 2018,
for an example). In addition, more complex outcomes than a simple binary endpoint
are becoming more frequent in dose-finding trials (see e.g. Yuan and others , 2007; Lee
and others , 2010, 2017) as they can carry more information about the drug’s mechanism
of action. Despite this, methods for studies with complex outcomes that do not require
monotonicity or a complex model are sparse to date.
Thinking more broadly about selecting one or more arms during a trial (the main
objective of many Phase II studies), different methods that consider arms being inde-
pendent have been proposed (see e.g. Stallard and Todd, 2003; Koenig and others , 2008;
Whitehead and Jaki, 2009; Magirr and others , 2012). Williamson and others (2016) have
recently advocated designs maximising the expected number of responses in small popula-
tions trials. As a result, adaptive randomisation methods and optimal multi-arm Bandit
(MAB) approaches are starting to be considered more commonly in Phase II clinical
trials. Although, MAB designs outperform other well-established methods of randomiza-
tion (e.g. fixed randomization) in terms of expected number of successes, they can suffer
low statistical power for testing comparative hypotheses. This problem corresponds to
the ‘exploration vs exploitation‘ trade-off (Azriel and others , 2011) and some rule-based
modifications have been proposed archive a better balance of the two objectives (see e.g.
Villar and others , 2015; Williamson and others , 2016). However, the majority of MAB
approaches consider univariate binary response only and hone in on the arm with the
largest effect by default and cannot be applied to clinical trials which aim to select the
TA corresponding to the target probability γe where γ is often between (0.7, 1). On the
other hand, model-based alternatives suffer from the problem of model misspecification.
Although, some of these challenges can be overcome by methods such as MCPmod (Bretz
and others , 2005), we believe that flexible alternatives that can be potentially used in the
described settings are required.
Overall, the research problems described above can be considered as the general issue
of correct identification of the TA whose response probability is closest to the percentile
0 < γ < 1 or equivalently in the multidimensional case, whose characteristics are closest
to the vector γ ∈ Sd where Sd is a d-dimensional unit simplex defined in (2.1). We
propose a general experimental design for studies with multinomial outcomes to solve this
generic problem. Based on developments in the information theory of context-dependent
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measures of information (Belis and Guiasu, 1968; Kelbert and Mozgunov, 2015; Kelbert
and others , 2016), we derive a criterion which governs arm selection in the experiment.
The criterion is based on the maximisation of the information gain when considering
an experiment with a particular interest in arms whose response probabilities are in
the neighbourhood of γ. Recently other designs using the information gain principle
have been proposed (see e.g. Barrett, 2016; Kim and Gillen, 2016). In contrast to these
methods, the proposed approach allows incorporation of the context of the outcomes
(e.g. avoid high toxicity or low efficacy) in the information measures themselves. This
is achieved by assigning a greater ”weight” to the information obtained about arms
with characteristics close to the desired level. Another difference to the majority of
information-theoretic approaches is that the design is based on the so-called ”patients’
gain” which allocates each new patient to the treatment that is considered best while
taking into account the uncertainty about the estimates for each arm. This leads to
fulfilling of statistical goals of the experiment under the ethical constraints.
The proposed criterion is not restricted to a particular model and can be used, for
examples, to govern selection within traditional parametric designs. However, motivated
by relaxing parametric and monotonicity assumptions, we demonstrate that good oper-
ating characteristics of the design can be achieved without employing these assumptions.
For the special case of a complex combination-schedule clinical trial the proposed design
has already been shown to be superior compared to currently employed methods and to
be practically applicable to an ongoing clinical trial (Mozgunov and Jaki, 2018). In this
work, we generalise the approach for an arbitrary number of outcomes and general class
of ”weight” functions, study the asymptotic behaviour of the design and compare the
performance to the currently used method in contexts of Phase I and Phase II trials.
The remainder of the paper is organized as follows: derivations of the criterion and
assignment rules are given in Section 2. The asymptotic behaviour is studied in Section
3. Section 4 presents illustrative examples of the design together with a comparisons to
alternative methods. We conclude with a discussion in Section 5.
2 Methods
The novel design is based on the maximisation of the information gain in the experiment
with an interval of the specific interest (neighbourhood of γ). Below, we derive an explicit
formula for the information gain in the context of a trial with multinomial outcomes.
2.1 Information-theoretic concepts
Consider a discrete random variable taking one of d values and a corresponding random
probability vector Z =
[
Z(1), Z(2), . . . , Z(d)
] ∈ Sd defined on a unit simplex
Sd = {Z : Z(1) > 0, Z(2) > 0, . . . , Z(d) > 0;
d∑
i=1
Z(i) = 1}. (2.1)
Assume that Z has a prior Dirichlet distribution Dir(v + J) where v =
[
v(1), . . . , v(d)
]T ∈
Rd+,
∑d
i=1 v
(i) = β and J is a d-dimensional unit vector. After n realizations of a discrete
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random variable in which x(i) outcomes of i are observed, i = 1, . . . , d, the random vector
Zn has a Dirichlet posterior distribution with density function
fn(p|x) = 1
B(x + v + J)
d∏
i=1
(
p(i)
)x(i)+v(i)
, B(x + v + J) =
∏d
i=1 Γ(x
(i) + v(i) + 1)
Γ
(∑d
i=1(x
(i) + v(i) + 1)
)
(2.2)
where p =
[
p(1), . . . , p(d)
]T
, x =
[
x(1), . . . , x(d)
]
,
∑d
i=1 x
(i) = n, 0 < p(i) < 1,
∑d
i=1 p
(i) = 1
and B(x + v + J) is the Beta-function and Γ(x) is the Gamma-function.
Let α =
[
α(1), . . . , α(d)
]T ∈ Sd be the vector in the neighbourhood of which fn con-
centrates as n → ∞. A classic question of interest in this setting is to estimate the
probability vector, α. The information required to answer the estimation question can
be measured by the Shannon differential entropy of fn (Cover and Thomas, 2012)
h(fn) = −
∫
Sd
fn(p|x)logfn(p|x)dp (2.3)
with convention 0 log 0 = 0. The classic formulation of the estimation question, however,
does not take into account the fact that an investigator would like to find the target
arm (TA) having pre-specified characteristics γ =
[
γ(1), . . . , γ(d)
] ∈ Sd. It does not also
reflect that one would like to have more precise estimation about the vector α for those
arms only which have characteristics close to γ. This is a consequence of the fact that
the classic information measures do not depend on the nature of the outcomes p, but
on the probability of the corresponding event f(p) and therefore are called context-free.
While it gives the notion of information great flexibility which explains its successful
application in various fields, the context-free nature might be considered as a drawback
in many application areas as it would be demonstrated below.
To take into account the context of the experiment and the nature of the outcomes p,
one can consider an estimation experiment with ”sensitive” area (i.e. the neighbourhood
of γ). The information required in such an experiment can be measured by the weighted
Shannon differential entropy (Belis and Guiasu, 1968; Clim, 2008; Kelbert and Mozgunov,
2015; Kelbert and others , 2016) of fn with a positive weight function φn(p)
hφn(fn) = −
∫
Sd
φn(p)fn(p|x)logfn(p|x)dp. (2.4)
The crucial difference between the information measures given in Equation (2.3) and
Equation (2.4) is the weight function, φn(p), which emphasizes the interest in the neigh-
bourhood of γ rather than on the whole Sd. It reflects that the information about the
probability vector which lies in the neighbourhood of γ is more valuable in the experi-
ment.
Due to the limited sample size in an actual studies, an investigator is typically inter-
ested in answering the question: Which arm has an associated probability vector closest
to γ while ensuring accurate estimation of the probability vector for the TA only. For
this question, the information gain from considering the experiment with sensitive area
equals to
∆n = h(fn)− hφn(fn). (2.5)
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Following the information gain approach, the first term in the equation above is the
information in a classic experiment using context-free measure, while the second (novel)
term is the information when the context of events is taken into account. Alternatively, ∆n
can be considered as an average amount of the additional statistical information required
when considering the context-dependent estimation problem instead of the traditional
one.
The information gain in Equation (2.5) requires specification of a weight function
which defines the ”value” of the information in different areas of the simplex Sd. To
track the influence of the weight function explicitly we consider a weight function in the
Dirichlet form:
φn(p) = C(x,γ, n)
d∏
i=1
(
p(i)
)γ(i)nκ
(2.6)
where κ ∈ (0, 1) is a parameter and C(x,γ, n) is a constant which is chosen to satisfy the
normalization condition
∫
Sd φn(p)fn(p|x)dp = 1. The parameter κ is restricted to the unit
interval to ensure asymptotically unbiased estimates of the vectorα: limn→∞
∫
Sd pφn(p)fn(p)dp =
α. This emphasises the interest in the identification of the TA for the small and moderate
sample sizes typical for many applications. The asymptotic behaviour of the information
gain, ∆n, for the family of weight functions (2.6) is studied in Theorem 1.
Theorem 1. Let h(fn) and h
φn(fn) be the standard and weighted differential entropies
of (2.2) with weight function (2.6). Let limn→∞
x(i)(n)
n
= α(i) for i = 1, 2, . . . , d and∑d
i=1 x
(i) = n, then
∆n = O
(
1
n1−2κ
)
as n→∞ if κ < 1
2
;
∆n = −1
2
(
d∑
i=1
(
γ(i)
)2
α(i)
− 1
)
n2κ−1 + ω(α,γ, κ, n) +O
(
1
nη(1−κ)−κ
)
as n→∞ if κ ≥ 1
2
where
ω(α,γ, κ, n) =
η∑
j=3
(−1)j−1
j
njκ−j+1
(
d∑
i=1
(
γ(i)
)j
(α(i))
j−1 − 1
)
and η = b(1− κ)−1c
Proof. The proof is given in the Appendix.
The information gain, ∆n, tends to 0 for κ < 1/2 which implies that assigning a
value of information with rate less than 1/2 is insufficient to emphasize the importance
of the context of the study. However, the limit is non-zero for κ ≥ 1/2. Following
the conventional information gain approach, one would like to make a decision which
maximises the statistical information in the experiment. The information gain ∆n is
always non-positive and for any fixed n its asymptotics achieves the maximum value 0
at the point α(i) = γ(i), i = 1, . . . , d (all constants are cancelled out). Indeed, Theorem
1 implies that when maximising the information gain ∆n, one tends to collect more
information about the arm which has characteristics α close to the target γ. To keep the
trackable solution which can be easily interpreted in applications, we construct the arm
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selection criterion using the leading term of the asymptotic expression for ∆n in Theorem
1:
δ(κ)(α,γ) :=
1
2
(
d∑
i=1
(
γ(i)
)2
α(i)
− 1
)
n2κ−1. (2.7)
Note that maximising the leading term of the information gain asymptotics is equiva-
lent to minimising δ(κ)(α,γ). Equation (2.7) can be considered as the measure of the
divergence between α and γ and the criterion which governs the selection such that the
information gain is maximised. The criterion (2.7) is intuitive as it reflects explicitly the
fact that an investigator tends to collect more information about the arm with proba-
bility vector close to γ, and also shares some desirable properties. Clearly, δ(κ)(·) ≥ 0
and δ(κ)(·) = 0 iff α = γ for all κ and n. The boundary values α(i) = 0, i = 1, . . . , d
correspond to infinite values of δ(κ)(α,γ) which is advocated by Aitchison (1992) as one
of the important properties for functions defined on simplex Sd. We construct the design
based on the selection criterion (2.7) below.
2.2 Selection criterion
Consider a discrete set ofm arms, A1, . . . , Am, associated with probability vectorsα1, . . . ,αm
and n1, . . . , nm observations. ArmAj is optimal if it satisfies δ
(κ)(αj,γ) = infi=1,...,m δ
(κ)(αi,γ).
To estimate δ(κ)(αi,γ) a random variable δ˜
(κ)
ni ≡ δ(κ)(Zni , γ) is introduced where Zni has
the Dirichlet distribution given in (2.2). Let us fix an arm Zni ≡ Zn and denote δ˜(κ)ni ≡ δ˜(κ)n .
It is a known that a Dirichlet random variable (after appropriate normalization) weakly
converges to a multivariate normal distribution. In fact, a stronger result can be shown
using the Kullback-Leibler distance D(f || g) = ∫R f(x)log f(x)g(x)dx where g and f are
probability density functions.
Theorem 2. Let Z˜n = Σ
−1/2 (Zn −α) be a random variable with pdf f˜n where pdf of Zn
is given in (2.2) with limn→∞
x(i)(n)
n
= α(i) for i = 1, 2, . . . , d,
∑d
i=1 x
(i) = n and where
Σ is a d-dimensional square matrix with elements Σ[ij] =
α(i)(1−α(i))
n
if i = j and Σ[ij] =
−α(i)α(j)
n
if i 6= j. Let Z be the multivariate Gaussian random variable MN (0, Id−1)
(Id−1 is the (d − 1)-dimensional unit matrix) with pdf ϕ and the differential entropy
h(ϕ) = 1
2
log
(
(2pie)d−1
)
. Then the Kullback-Leibler divergence of ϕ from f˜n tends to 0
as n→∞ which implies that Z˜n weakly converges to Z.
Proof. The proof in given in the Appendix.
Using Theorem 2 the following result can be obtained for the proposed criterion.
Theorem 3. Under the assumptions of Theorem 2, let δ˜
(κ)
n = δ(κ)(Zn,γ), ∇δ(κ)(z,γ) =[
∂δ(κ)(z,γ)
∂z(1)
, . . . , ∂δ
(κ)(z,γ)
∂z(d)
]T
, δ¯
(κ)
n = Σ¯−1/2
(
δ(κ)(Zn,γ)− δ(κ)(α,γ)
)
where Σ¯ = ∇TαΣ∇α
and ∇α ≡ ∇δ(κ)(z,γ) evaluated at z = α. Let Z¯ be a standard Gaussian RV. Then,
limn→∞ Eδ˜(κ)n = δ(κ)(α,γ), limn→∞Vδ˜(κ)n = 0, and δ¯(κ)n weakly convergences to Z¯.
A single summary statistics for δ(κ)(Zn,γ) is needed to select the most promising
arm in the sequential experiment. While a Bayesian estimator can be used, we will
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focus on the intuitively clear and simple ‘plug-in‘ estimator, δˆ(κ)(pˆn, γ) ≡ δˆ(κ)n with pˆn =
[pˆ
(1)
n , . . . , pˆ
(i)
n , . . . , pˆ
(d)
n ] and pˆ
(i)
n = x
(i)+v(i)
n+β(i)
, i = 1, . . . , d, the mode of the posterior Dirichlet
distribution. The estimator for the arm Aj takes the form
δˆ(κ)nj = δ
(κ)(pˆnj ,γ) =
1
2
(
d∑
i=1
(
γ(i)
)2
pˆ
(i)
nj
− 1
)
n2κ−1j , j = 1, 2, . . . ,m. (2.8)
Note that by Theorem 3 for any ε > 0 limnj→∞ P
(
δ˜
(κ)
nj ∈ [δˆ(κ)nj − ε, δˆ(κ)nj + ε]
)
= 1. The
statistics (2.8) is used to govern the selection among arms during the experiment. Note
that the estimator above requires a vector of prior parameters vj, j = 1, . . . ,m to start
the experiment. This choice implies an initial ordering in which an investigator would
like to test the arms before the data is available.
2.3 Specific Assignment rules
The criterion (2.7) summarizes the arm’s characteristics and can be applied to different
types of sequential experiments. We consider two assignment rules: Rule I which ran-
domizes between arms and Rule II which selects the “best” arm. These rules follow the
setting of the motivating clinical trials: Rule II is widely used in Phase I trials where the
randomization to all doses is not ethical or in the typical MAB setting where the primary
goal is to maximize the number of successes. Note that randomization (when is ethical)
allows to decrease the probability of identifying a suboptimal arm (Thall and Wathen,
2007).
2.3.1 Rule I: Randomization
Under Rule I, the arm used next in the experiment is randomised with probabilities w˜j ≡
1/δ˜
(κ)
nj∑m
i=1 1/δ˜
(κ)
ni
, j = 1, . . . ,m and from Theorem 3 wj = limn1,n2,...,nm→∞ E (w˜j) =
1/δ
(κ)
nj∑m
i=1 1/δ
(κ)
ni
.
When no observations have yet been collected, the procedure randomizes according to
the criterion based on the prior distribution alone, δˆ
(κ)
βj
, j = 1, . . . ,m. Then, given nj
observations, xj outcomes for arm Aj, j = 1, . . . ,m and using the ‘plug-in‘ estimator (2.8),
arm Aj is selected with probability wˆj = 1 if δˆ
(κ)
nj = 0 and with probability
wˆj =
1/δˆ
(κ)
nj∑m
i=1 1/δˆ
(κ)
ni
if δˆ(κ)ni > 0, i = 1, . . . ,m. (2.9)
The method proceeds until N observations are attained. The arm Aj satisfying
δˆ
(1/2)
Nj
= inf
i=1,...,m
δˆ
(0.5)
Ni
. (2.10)
is adopted for the final recommendation, where Ni is a total number of observation
on an arm Ai, i = 1, 2, . . . ,m. The value κ = 0.5 in (2.10) is used so that the final
recommendation is not penalized by the sample size.
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2.3.2 Rule II: Select the best
Let N be a total sample size and begin with the experiment with the arm that minimizes
δˆ
(κ)
βj
, j = 1, . . . ,m. Given nj observations, xj outcomes for the arm Aj, j = 1, . . . ,m and
using the ‘plug-in‘ estimator, an arm Aj is selected if it satisfies δˆ
(κ)
nj = infi=1,...,m δˆ
(κ)
ni .
The method proceeds until the total number of N is attained. Again, we adopt Aj as in
(2.10) for the final recommendation.
2.4 Criterion in the context of clinical trials
Further in the examples (Section 4) we apply the novel selection criterion to Phase I
and Phase II clinical trials. In this case the arms are the different treatments (doses,
combinations, schedules,...) and the goal is to find the treatment corresponding to specific
toxicity (efficacy) characteristics. As the proposed information gain and corresponding
selection criterion tends to assign the next patients to the best estimated TA during the
trial, the criterion based on ∆n is a patient’s gain (also known as ‘best intention‘ ) criterion
as classified by Whitehead and Williamson (1998). The balance in the ‘exploration vs
exploitation‘ trade-off is tuned by the term n2κ−1j reflecting the penalty on the number of
observations on the same arm (i.e. many observations on one arm would favour selection
of other arms). This implies that the design will keep selecting a specific arm only, if
the corresponding estimate, α is close γ. As the trial progresses the design requires
an increasing level of confidence that the selected arm is the TA. Clearly, κ = 1/2
corresponds to no penalty and is of particular interest in trials with small sample sizes
while larger values of κ > 1/2 correspond to a greater interest in the statistical power of
the experiment. Importantly, the first term in Equation (2.7) guarantees that the vast
majority of patients will be assigned to the TA even for κ > 1/2.
As many Phase I and Phase II clinical trials consider a binary endpoint d = 2 (toxic-
ity:yes/no or response:yes/no), we focus on this case in the examples. Then, (2.2) reduces
to the Beta-distribution and the proposed criterion takes the form
δˆ(κ)nj (α, γ) =
1
2
(pˆ
(i)
nj − γ)2
pˆ
(i)
nj (1− pˆ(i)nj )
n2κ−1j (2.11)
which is a normalized distance between pˆ
(i)
nj and γ. Note that this is not equivalent to the
Euclidean distance (pˆ
(i)
nj − γ)2 which is a commonly used criterion for selection (see e.g.
Shen and O’Quigley, 1996). As the criterion tends to assign patients to the TA, it still
has the Euclidean distance term in the nominator. However, it also takes into account
the uncertainty in the denominator which is a variance of the probability of a binary
event. The denominator can be also considered as a penalty term which ”drives away”
the allocation from the bounds (pˆ
(i)
nj = 0 or pˆ
(i)
nj = 1) as the boundary values correspond
to the infinite value of the criterion. Note that, as the maximum variance of the binary
probability is achieved at pˆ
(i)
nj = 0.5, so the criterion favours greater values of pˆ
(i)
nj which
can be unethical if the objective of a study is to control the risk of toxicity. We will study
whether the construction of the criterion creates any practical limitation in the context
of Phase I clinical trial in Section 4.2.
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3 Asymptotic behaviour
Considering the asymptotic behaviour of a procedure ensures that the experimental design
becomes more accurate as a sample size grows (Azriel and others , 2011). Recall that the
goal of the sequential experiment is to find an arm j which corresponds to the minimum
value δj ≡ δ(αj,γ) among all arms using random variables δ˜(κ)i = δ(κ)(Zni ,γ), i =
1, . . . ,m. Denote the arm to be selected by ν = arg mini=1,...,m δ˜
(κ)
i . Below, we consider the
risk-adjusted average approach (Polley and Cheung, 2008) and the probability of correct
selection (PCS) (Cheung, 2013) AN =
1
m
∑m
j=1 Ppij(ν = j) where Ppij is the probability
computed under the vector pij = [α1,j, . . . , αm,j]
T , 1 ≤ j ≤ m, which assumes that αj,j
corresponds to the TA. The design is consistent if limN→∞AN =∞. The main result of
this section is formulated in the following Theorem.
Theorem 4. Let us consider the experimental design with a selection criteria based on
δ˜
(κ)
ni , m arms and corresponding true probabilities vectors αi, i = 1, . . . ,m. Then,
(a) The design is consistent under Rule I (2.3.1) for κ ≥ 0.5.
(b) The design is consistent under Rule II (2.3.2) for κ > 0.5.
Proof. The proof is given in the Appendix.
4 Examples
In this section the performance of the proposed experimental design is studied in the
context of Phase I and Phase II clinical trials under different assignment rules. We will
refer to our proposal as the Weighted Entropy (WE) design (WEI under Rule I and
WEII under Rule II) and compare its performance to several well-established alternative
approaches. All computations have been conducted using R (R Core Team, 2015).
4.1 Phase II clinical trial
4.1.1 Setting
Consider a Phase II clinical trial whose primary endpoint is a binary measure of efficacy
(e.g. response to treatment). The goals of the study are (i) to find the most effective
treatment and (ii) to treat as many patients as possible on the optimal treatment. Clearly,
Rule I is preferable for the first goal and Rule II for the second one. We consider two
hypothetical trials, each with m = 4 treatments, investigated by Villar and others (2015)
for Multi-Arm Bandit models (MAB). We compare the performance of the proposed
approach to the MAB approach based on the Gittins index (Gittins and Jones, 1979),
which is the optimal design in terms of maximising expected number of successes (ENS),
and to fixed and equal randomization (FR) which is best in terms of the statistical power.
Trial 1 investigates N1 = 423 and the true efficacy probabilities are (0.3, 0.3, 0.3, 0.5)
while Trial 2 considers N2 = 80 and the scenario (0.3, 0.4, 0.5, 0.6). Following the original
application we consider the hypothesis H0 : p0 ≥ pi for i = 1, 2, 3 with the family-wise
error rate calculated at p0 = . . . = p3 = 0.3, where p0 corresponds to the control treatment
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efficacy probability. The Dunnett test (Dunnett, 1984) is used for the hypothesis testing
in the FR setting. The hypothesis testing for MAB and WE design is performed using
an adjusted Fisher’s exact test (Agresti, 1992). The adjustment chooses the cutoff values
to achieve the same type-I error as the FR. The Bonferroni correction is used for MAB
and WE designs to correct for the multiple testing and the family-wise error rate is set
to be less or equal to 5%. Characteristics of interest are (i) the type-I error rate (α),
(ii) statistical power (1 − η), (iii) the expected number of successes (ENS) and (iv) the
average proportion of patients on the optimal treatment (p∗).
The WE design requires specification of the target value which can be specified in
many clinical trial by clinicians. This can be defined as the maximum efficacy that they
expect to see for the particular diseases. Below we consider the most challenging setting
in which no target value is specified and the goal is to simply maximise the number of
successes (as in MAB). To achieve this we set the target probability to a value close
to 1. The target γ = 0.999 is used which corresponds to the aim ”to find the arm
with the highest efficacy probability”. The vector of the prior mode probabilities p(0) =
[0.99, 0.99, 0.99, 0.99]T is chosen to reflect no prior knowledge about which arm has the
highest success probability and that each treatment is considered as highly efficacious until
data suggests otherwise. This choice of prior reflects the equipoise principle (Djulbegovic
and others , 2000). We choose β0 = 5 to ensure enough observations on the control arm
and β1 = β2 = β3 = 2 to reflect no prior knowledge for competing arms. We fix κ = 0.5
for WEI and use different values of κ for WEII.
4.1.2 Results
The trade-off between the expected number of successes (ENS) and the statistical power
for different values of the penalty parameter κ under Rule II is illustrated in Figure 1. In
both trials, greater values of κ correspond to greater power and lower ENS as the increase
in penalty tends to more diverse allocations. The exception is κ ∈ (0.5, 0.55) in Trial 1
where the inconsistency for κ = 0.5 leads to locking-in on the suboptimal treatment.
We choose two values of κ for the subsequent comparison. These choices correspond to
(i) high ENS, but unacceptable power (dashed line) and (ii) slightly reduced ENS, but
higher power (dotted line).
The operating characteristics of considered designs in Trial 1 are given in Table 1.
Under the null hypothesis, the performance of all methods is similar and the type-I error
is controlled. Under the alternative hypotheses, the WEII design with κ = 0.55 performs
comparably to the MAB in terms of the ENS, but yields almost 10% points increase in
power. Nevertheless, it has unacceptable low statistical power which can be increased by
using higher values of the penalty parameter (κ = 0.65). It leads to an increase in the
power from 0.53 to 0.86 at the cost of the slight (≈ 4%) decrease in the ENS. In fact
WEII then has comparable power to the FR, while treating almost 40 more patients on
the superior treatment. Another way to increase the statistical power is to use WEI for
which both the associated power and the ENS is higher than for the FR.
The operating characteristics of the designs for Trial 2 with fewer patients and a
linear increasing trend is given in the Table 2. Under the null hypothesis, all designs
10
0.50 0.60 0.70 0.80
17
5
18
5
19
5
Trial 1 
 
EN
S
0.5 0.6 0.7 0.8 0.9 1.0
38
39
40
41
42
Trial 2
 
EN
S
0.50 0.60 0.70 0.80
0.
2
0.
4
0.
6
0.
8
1.
0
κ
Po
w
e
r
0.5 0.6 0.7 0.8 0.9
0.
0
0.
2
0.
4
κ
Po
w
e
r
Figure 1: ENS and power (fixed cutoff value) for the WE design under the Rule II for different
κ. Dashed lines correspond to the values chosen for the subsequent study. Results are based on
104 replications
Table 1: Operating characteristics of the WE design under the Rule I (WEI), under the
Rule II (WEII) for different κ (in brackets), MAB design and FR in Trial 1 with N = 423
under the null and alternative hypothesises. Results are based on 104 replication.
Method
H0 : p0 = p1 = p2 = p3 = 0.3 H1 : p0 = p1 = p2 = 0.3, p3 = 0.5
α p∗(s.e) ENS(s.e.) (1− η) p∗(s.e.) ENS (s.e.)
MAB 0.05 0.25 (0.18) 126.68 (9.4) 0.43 0.83 (0.10) 198.25 (13.7)
FR 0.05 0.25 (0.02) 126.91 (9.4) 0.82 0.25 (0.02) 147.91 (9.6)
WEI (0.50) 0.05 0.24 (0.05) 126.84 (9.5) 0.88 0.39 (0.06) 159.90 (11.0)
WEII (0.55) 0.05 0.21 (0.20) 126.89 (9.4) 0.55 0.83 (0.18) 197.13 (17.8)
WEII (0.65) 0.05 0.23 (0.13) 126.86 (9.4) 0.87 0.74 (0.10) 189.26 (13.7)
perform similarly and type-I errors are controlled at the 5% level. Under the alternative
hypothesis, the MAB and WEII with κ = 0.55, again, yield the highest (and similar) ENS
among all alternatives, but also low statistical power. The WEI or increased κ for WEII
result in a considerable power increase. Both designs have a greater (or similar) power
and result in more ENS than the FR.
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Table 2: Operating characteristics of the WE design under the Rule I (WEI), under the
Rule II (WEII) for different κ (in brackets), MAB design and FR in Trial 2 with N = 80
under the null and alternative hypothesises. Results are based on 104 replication.
Method
H0 : p0 = p1 = p2 = p3 = 0.3 H1 : pi = 0.3 + 0.1i, i = 0, 1, 2, 3
α p∗(s.e) ENS(s.e.) (1− η) p∗(s.e.) ENS (s.e.)
MAB 0.00 0.25 (0.13) 23.97 (4.10) 0.01 0.49 (0.21) 41.60 (5.4)
FR 0.05 0.25 (0.04) 24.02 (4.10) 0.50 0.25 (0.04) 35.98 (4.3)
WEI (0.50) 0.05 0.23 (0.07) 23.92 (4.11) 0.59 0.33 (0.10) 37.55 (4.7)
WEII (0.55) 0.01 0.20 (0.15) 24.01 (4.10) 0.11 0.50 (0.27) 40.72 (5.9)
WEII (0.65) 0.05 0.22 (0.12) 23.96 (4.08) 0.52 0.47 (0.21) 40.19 (5.4)
Overall, WE designs can perform comparably to the optimal MAB design in terms of
the ENS, but with greater statistical power for both large and small sample sizes. They
have similar statistical power to the FR, but with the considerably greater ENS. The ENS
and power trade-off can be tuned via the built-in parameter κ. Although, some modifi-
cation to the MAB designs were proposed (e.g. see Villar and others , 2015) to prevent
the low statistical power, the majority of those are ruled-based. The proposed approach
allows to avoid any algorithm-based rules and keeps the procedure fully adaptive. Addi-
tionally, the computation of the Gittens index for the MAB design is not trivial, requires
special attention and is widely discussed in the literature (e.g. see Villar and others , 2015,
and reference there in). Some of them require calibration and can be computationally
intensive. In contrast, the proposed criterion is extremely simple and easy to compute.
While the proposed designs are compared for the target γ = 0.999, similar performance is
obtained for the problem of seeking an arm associated with a given response probability
(γ ∈ (0.7, 1)). This is, for example, of interest when seeking the effective dose 80 (ED80),
the dose for which 80% of subjects respond to the treatment.
4.2 Phase I clinical trial
4.2.1 Setting
To study the WE design in the context of Phase I clinical trials, let us consider m = 7
arms, N = 20 patients and the arm selection allowed after each patient. The goal is
to find the arm (which could be combination, schedule or combination-schedule) with a
toxicity probability closest to γ = 0.25. In these studies randomization to all arms is
not ethical for safety reasons and therefore, Rule II and κ = 0.5 are used. We would
like to emphasize that we do not consider the classic dose-escalation problem in which
the doses can be put according to increasing toxicity and focus on the setting in which
clinicians cannot put arms according to increasing toxicity (as e.g. often in scheduling
trials). While clinicians will be able to provide a presumed ordering of the arms, this
order might be misspecified.
We consider scenarios in which the prior order chosen by clinicians is either correct
or misspecified. The scenarios with correctly specified ordering have a monotonic arm-
toxicity relationship and the scenarios with misspecified ordering have a non-monotonic
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relationship. The investigated scenarios are shown in Figure 2 and include a variety of
monotonic and non-monotonic shapes as well as one setting with highly toxic arms only.
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Figure 2: Toxicity scenarios. The optimal arm is marked by a triangle and the maximum
tolerated toxicity γ = 0.25 is marked by dashed horizontal line. The monotonic scenarios
(1-3, 6) correspond to correctly prespecified ordering of arms according to increasing
toxicity and non-monotonic scenarios (4-5) to misspecified ordering of arms.
It is assumed that limited information about treatments is available and a linear
increase in the toxicity probabilities is expected such that pˆβ1 < pˆβ2 < . . . < pˆβ7 . For
safety reasons, the trial is required to start at d1. An ‘operational‘ prior, that is a prior
that gives good operating characteristics under different scenarios, is calibrated. Details
on the calibration are given in the Appendix. The resulting prior uses β = 1 and prior
toxicity risk modes of pˆ = [0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55]T. For the simulation study
below, the penalty parameter is fixed at κ = 0.5 due to the small sample size.
The WE design is compared to common Phase I designs. Specifically the Bayesian
Continual Reassessment Method (CRM) (O’Quigley and others , 1990) and Escalation
with Overdose Control (EWOC) (Babb and others , 1998) are considered as methods
that assume a monotonic toxicity relationship. Additionally, the partial ordering CRM
(POCRM, Wages and others , 2011) which relaxes the monotonicity assumption is also
considered. It uses the original CRM design with additional randomization among a
pre-specified set of orderings. In our comparison we consider only correct orderings
(Table 3) to allow for the best possible performance of the POCRM under the evaluated
scenarios. The same prior toxicity probabilities pˆ and a rough prior distribution of the
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Table 3: Orderings for POCRM.
Order
1 (1,2,3,4,5,6,7)
2 (1,2,7,6,5,4,3)
3 (7,6,5,4,1,2,3)
model parameters were chosen for the model-based alternatives. Finally, we include the
non-parametric optimal benchmark (O’Quigley and others , 2002) which provides the best
theoretical performance if the patients’ complete toxicity profiles are known.
The main characteristics to consider are: (i) the proportional of correct selections
and (ii) the average number of toxic responses. The bcrm package (Sweeting and others ,
2013) is used for CRM and EWOC and the pocrm package is used for POCRM. For the
proposed method and the non-parametric optimal design one-million-fold simulations
are used while 100,000-fold simulations are used for the model-based methods due to
computational constraints.
4.2.2 Safety constraint
For ethical reasons an escalation procedure should be planned so that only few patients
are assigned to highly toxic treatments which is typically achieved by the use of a safety
constraint. The majority of existing safety constraints are based on the assumption of
monotonicity and hence are not suitable for the proposed design. We adopt the following
safety constraint instead. The treatment Aj is safe if after n patients
∫ 1
γ∗ fnj(p)dp ≤ θnj
where γ∗ is an upper toxicity threshold, θnj controls the overdosing probability and fnj
is the posterior Beta distribution for the toxicity probability. Note that the overdosing
threshold θnj changes as the trial progresses. It should be a decreasing function of n
with θ0 = 1 to give a possibility to test all the treatments (if data suggests so) and
θfinal ≤ 0.3 to ensure that the final recommendation is safe. As an illustration, the
linear non-increasing θn = max(1 − rn, θfinal) is used with r > 0. We have calibrated
the parameters of the safety constraints (details in the Appendix) and used γ∗ = 0.45
and r = 0.035 in the simulations. Similar safety constraints were incorporated in the
model-based methods.
4.2.3 Results
The simulation results in monotonic scenarios 1-3 are given in Table 4. The WE design
performs comparably to the CRM and POCRM designs and recommends the correct
treatment with the probability nearly 0.25 and 0.30 in scenario 1 and 2. In scenario 1 the
WE design underestimates the target treatment and recommends a less toxic treatment
more often due to the safety constraint. Despite that, the performance of all methods is
not far from the non-parametric optimal benchmark which shows that the detection of
the target treatment is quite challenging. Proportions of terminations are close to 0 and
the average number of toxic responses is largely the same. For the EWOC, the level of
the target treatment is underestimated in both scenarios.
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Table 4: The operating characteristics of the WE, CRM, POCRM and EWOC designs.
‘Term‘, ‘T‘ and N¯ correspond to the termination proportion, the average number of toxic
responses and the average number of patients, respectively. The most likely recommen-
dation is in bold, the actual target regimen is in italics.
d1 d2 d3 d4 d5 d6 d7 Term T N¯
Scenario 1. Linear response
Scenario 0.06 0.12 0.15 0.18 0.24 0.36 0.40
Optimal 0.92 9.12 10.60 14.44 31.54 27.50 5.87
WE 7.03 14.72 23.33 30.11 23.34 1.39 0.05 0.1 3.36 20.0
CRM 2.66 7.21 14.17 20.58 26.62 15.95 12.53 0.3 4.38 19.9
POCRM 2.69 11.25 22.30 15.73 22.60 20.62 4.60 0.2 4.94 20.0
EWOC 8.06 13.80 20.30 23.70 20.20 9.62 3.88 0.4 3.76 18.8
Scenario 2. Logistic shape
Scenario 0.10 0.18 0.25 0.32 0.50 0.68 0.82
Optimal 6.05 29.03 30.12 28.27 6.48 0.05 0.00
WE 16.78 26.43 29.54 22.51 3.76 0.11 0.00 0.9 5.23 20.0
CRM 17.24 25.88 28.70 19.37 6.24 0.56 0.04 1.9 4.84 19.7
POCRM 14.98 27.32 27.89 18.50 6.70 1.04 1.86 1.7 5.54 20.0
EWOC 28.72 27.66 24.32 13.65 4.21 0.00 0.00 1.4 3.27 18.0
Scenario 3. J shape
Scenario 0.15 0.20 0.50 0.55 0.60 0.65 0.70
Optimal 29.87 58.31 10.0 2 1.69 0.11 0.00 0.00
WE 38.07 44.65 6.59 3.44 1.48 0.28 0.02 5.5 5.94 19.8
CRM 37.47 37.85 17.41 2.92 0.36 0.07 0.00 3.9 5.10 19.4
POCRM 33.57 37.76 13.27 2.55 0.54 1.33 6.04 4.9 6.06 19.8
EWOC 51.00 26.11 11.01 0.88 0.13 0.00 0.00 10.9 3.60 16.8
In scenario 3, the WE design shows a better performance than the model-based al-
ternatives with nearly 45% of correct recommendations against about 40% for CRM and
POCRM. The safety constraint allows to prevent the recommendation of highly toxic
treatments and controls the total number of toxic responses. Again, the EWOC under-
estimates the target therapy, but results only in 3 toxic responses compared to 5 for the
CRM and 6 toxicities for the WE and the POCRM. As expected, methods that relax
monotonic assumption result in more toxic responses that monotonicity based designs.
The results for non-monotonic (Scenarios 4-5) and unsafe (Scenario 6) cases are given
in Table 5. As expected, the designs based on the monotonicity assumption are not able
to find the target treatment in non-monotonic settings. Comparing other designs, the
WE design has a substantial advantage. It finds the correct arm with the probability
nearly 0.28 compared to 0.20 for the POCRM while exposing nearly the same number of
patients to toxic treatments. The safety constraint allows recommendation of the optimal
treatment even in non-monotonic scenarios where the target treatment lies beyond the
toxic treatments (d3 − d4).
Considering Scenario 6, the WE design terminates earlier with probability 0.8 and
performs similar to the POCRM and EWOC. It outperforms the CRM which recommends
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Table 5: The operating characteristics of the WE, CRM, POCRM and EWOC designs.
‘Term‘, ‘T‘ and N¯ correspond to the termination proportion, the average number of toxic
responses and the average number of patients, respectively. The most likely recommen-
dation is in bold, the actual target regimen is in intalics.
d1 d2 d3 d4 d5 d6 d7 Term T N¯
Scenario 4. Inverted-U shape
Scenario 0.05 0.10 0.40 0.35 0.25 0.15 0.12
Optimal 0.88 7.36 19.12 18.96 38.47 13.64 1.57
WE 14.11 19.13 11.77 18.27 27.90 8.50 0.23 0.1 4.26 20.0
CRM 4.26 19.90 17.70 6.31 2.84 3.00 46.10 0.3 3.26 19.9
POCRM 2.87 11.39 11.75 9.32 19.11 33.94 11.62 0.2 4.29 20.0
EWOC 7.18 24.90 18.60 3.79 2.52 3.79 30.60 6.6 2.73 18.9
Scenario 5. Inverted-U shape
Scenario 0.35 0.40 0.40 0.35 0.25 0.15 0.10
Optimal 16.18 3.01 3.01 16.18 39.46 18.65 3.51
WE 15.57 12.65 13.31 18.27 27.92 8.90 0.58 9.9 5.81 19.7
CRM 47.41 2.51 0.97 0.48 0.72 0.40 30.10 27.3 4.27 16.0
POCRM 16.81 5.98 5.66 12.42 20.10 23.13 10.23 9.7 5.14 19.5
EWOC 30.75 1.26 0.78 0.47 0.47 0.31 9.78 56.2 3.30 11.0
Scenario 6. Unsafe
Scenario 0.50 0.55 0.60 0.65 0.70 0.75 0.80
Optimal 80.53 16.35 3.10 0.02 0.00 0.00 0.00
WE 13.63 5.53 2.45 0.88 0.27 0.06 0.00 77.2 8.02 14.2
CRM 32.24 0.32 0.08 0.00 0.00 0.00 0.00 67.4 5.33 10.3
POCRM 13.18 0.57 0.12 0.04 0.01 2.06 0.08 83.9 7.12 12.5
EWOC 16.17 0.00 0.12 0.00 0.00 0.00 0.00 83.7 3.07 6.1
a highly toxic arm with a larger probability (32.56% against 19.16%). However, methods
that relax the monotonicity assumption result in more toxic responses and require more
patients on average to come to the termination conclusion. While the CRM and the
EWOC require 5 and 6 patients only, it takes nearly 14 and 13 patients for the WE
and POCRM as they explore all arms before concluding none is safe. This, however,
would not be considered as a severe drawbacks of these methods as in many application
clinicians would stop the trial for safety reasons based on extensive patients profile.
Summarizing, the proposed design performs comparably to the model-based approaches
in monotonic settings and clearly outperforms them in non-monotonic ones. Importantly,
despite the denominator of the proposed criterion which might favour slightly more toxic
arms, the design does not cause any practical concerns as soon as the allocation is re-
stricted to the safety set. In other words, the criterion allocates the patients to the best
estimated TA taking into account information about the uncertainty in the estimates and
about the safety set. Importantly, the time-varying safety constraint achieves the goals
motivated by the ethical concerns while not preventing the target treatment selection in
safe and non-monotonic scenarios. One can conclude that the design is ethical and can
be applied in practice.
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5 Discussion
In this work, we propose a family of criteria for selecting the best arm in experiments with
multinomial outcomes. The novel criterion leads to accurate selection without the need
for parametric or monotonicity assumptions. The fundamental property of the criterion
is the infinite penalization of the bounds which was argued to be a crucial property for
a parameter defined on the restricted space (Aitchison, 1992). This property drives the
allocation away from the bounds of a restricted space to the neighbourhood of the target
value. The consistency conditions of the proposed design and exact rate for the special
case of binary outcomes are obtained. It is shown how one can benefit from the proposed
design in Phase I and Phase II clinical trials. The proposal was demonstrated to have a
comparable or better characteristics than other alternatives. It preserves flexibility and
allows to tailor the design parameters in light of the investigation goal. Additionally,
the design is computationally simple and a large set of simulation can be performed in a
feasible time.
Despite clinical trials being used as the main motivation throughout, the design can
be applied to a wide range of problems of a similar nature. For example, applications
where the MAB approach has found application: online advertising, portfolio design,
queuing and communication networks, etc. (see Gittins and others , 2011, and references
there in). On top of that, the proposed design can be used in more general problems
of percentile estimation rather than the identification of the highest success probability.
It is important to emphasize that the derived selection criterion can be also applied in
conjunction with a parametric models which also expands its possible applications. In
fact, the parameters can be estimated by any desirable method and then ‘pluged-in‘ in
the criterion which preserves its properties.
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Appendices
A Proofs
Proof of Theorem 2.1
Proof. The problem reduces to computing integrals of the following forms∫
Sd
log
(
p(i)
)x(i)
fn(p)dp = x
(i)
(
ψ
(
x(i) + 1
)− ψ (n+ d)) , i = 1, 2, . . . , d,
∫
Sd
log
(
p(i)
)x(i)
φn(p)fn(p)dp = x
(i)
(
ψ
(
x(i) + γ(i)nκ + 1
)− ψ (n+ nκ + d)) , i = 1, 2, . . . , d
where ψ(x) = d
dx
logΓ(x) is the digamma function. Using the asymptotics of the digamma
function (Gradshteyn and Ryzhik, 2014), Taylor series expansion and simplifying terms,
the results immediately follows.
Proof of Theorem 2.2
Proof. Following the proof of Theorem 2.1, one can obtain that h (fn) = logB (x + v + J)+
nψ (n+ d)−∑di=1 x(i)ψ (x(i) + 1) . As n→∞
h (fn) =
1
2
log (2pie)d−1 +
1
2
log
∏d
i=1 α
(i)
nd−1
+O
(
1
n
)
.
Using that h
(
f˜n
)
= h (fn)+log |det
(
Σ−1/2
) | (Cover and Thomas, 2012) where det(A) is
a determinant of the matrix A and log |det (Σ−1/2) | = −1
2
log
∏d
i=1 α
(i)
nd−1 +O
(
1
n
)
as n→∞.
Then,
D(f˜n || ϕ) = −h
(
f˜n
)
−
∫
Sd
f˜n(p) logϕ(p)dp
= −1
2
log (2pie)d−1 +
1
2
log (2pi)d−1 +
1
2
∫
Sd
d−1∑
i=1
(
p(i)
)2
f˜n(p)dp +O
(
1
n
)
= O
(
1
n
)
,
as
∫
Sd
∑d−1
i=1
(
p(i)
)2
f˜n(p)dp = d − 1 + O
(
1
n
)
is the sum of the second moments. Us-
ing Pinsker’s inequality (Csiszar and Ko¨rner, 2011) it implies the convergence in total
variation (Cover and Thomas, 2012) which implies the weak convergence.
Proof of Theorem 3.1
Proof. (a) Rule I. Under Rule I the proportion of observations on each arm converges
to a constant (Theorem 2.3). Therefore, it is initially assumed that it is fixed and the
probability measures below are conditional on the allocation proportion.
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We start from from κ = 1/2 and adopt notation δ˜
(1/2)
ni ≡ δ˜i. Denoting C¯k,k+1 ≡ {δ˜k <
δ˜k+1} and Ck,k+1 ≡ {δ˜k > δ˜k+1} we find that
{ν = k} ⇔ {C¯k,1 ∩ C¯k,2 ∩ . . . ∩ C¯k,k−1 ∩ C¯k,k+1 ∩ . . . ∩ C¯k,m} ⇔ {∩mi=1,i 6=kC¯k,i}.
Using DeMorgan’s law and Boole’s inequality (Resnick, 2013), one can obtain
P(ν = k) = 1− P (∪mi=1,i 6=kCk,i) ≥ 1− m∑
i=1,i 6=k
P (Ck,i) = 1−
m∑
i=1,i 6=k
P
(
δ˜k > δ˜i
)
(A.1)
where
P
(
δ˜k > δ˜i
)
= P
(
δ˜i − δi − δ˜k + δk
Σk,i
<
δk − δi
Σk,i
)
≈ Φ
(
δk − δi
Σk,i
)
(A.2)
with Φ(.) denoting the distribution function of a standard normal random variable,
Σk,i = (Σk + Σi)
1/2 and Σk the variance corresponding to arm k as in the Theorem
2.3. As arms k and i are independent, there are two independent random variables in
the left-hand side of the second term in (A.2) and each of them converges to a Gaussian
random variables (Theorem 2.3). Therefore, the sum converges to a standard Gaussian
random variable after an appropriate normalization. Consequently, for j = 1, . . . ,m
Ppij (ν = j) ≥ 1−
m∑
i=1,i 6=j
Φ
(
δj,j − δi,j
Σj,i
)
(A.3)
By the construction of pij, δj,j − δi,j < 0. The number of observations on each arm Ni is
proportional to the total sample size N under Rule I: Nj ' wjN and Nj ' wj−1N where
an ' bn means that limn→∞ anbn = 1. Thus,
δm,m − δi,j
Σm,i
' c
√
N (A.4)
where c is a negative constant. Plugging-in terms in the accuracy formula, we obtain
that limN→∞AN ≥ 1.
For κ > 1/2, the probability of the final selection in the experiment is still given by
(A.1) for κ = 1/2 as the penalty term is not taken into account for the final recommen-
dation. Then, the only difference is the number of observation on each arm, proportional
to the total number of patients Nj ' lj(N)N with lj depending on N . This results in a
different constant c < 0 in (A.4), but in the unchanged rate
√
N due to the same rate in
both nominator and denominator in Equation (2.8) with respect to N .
Binary outcomes
While the asymptotic result (A.2) is given in terms of Σk,i, it can be written explicitly.
In the special case of binary outcomes d = 2, Σk,i =
√
σ2k + σ
2
i and σj = |δi′|
√
αj(1−αj)
nj
,
j = i, k with
∂δ
(κ)
i (z, γ)
∂z
∣∣∣∣∣
z=α
= δ
(κ)
i
′
=
(γ − α)(γ(2α− 1)− α)
α2(1− α)2 .
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Therefore,
Φ
(
δk − δi
σk,i
)
= Φ
( √
nkni (δk − δi)√
nkαi(1− αi)(δi′)2 + niαk(1− αk)(δk ′)2
)
.
From the expression above, the rate obtained in (A.4) is explicit.
(b) Rule II. Consider κ = 1
2
. The design based on this measure and on its point estimate
is inconsistent as it does not guarantee an infinite number of patients on all arms. We use
an example with two arms only with the arm A1 being the optimal. Suppose that prior
parameters are specified such that δˆβ2  δˆβ1 and δ2  δˆβ1 , so A2 is selected initially.
While the number of observations on the arm 2 increases and the estimate δˆ2 approaches
the true value δ2 (Theorem 2.3), the estimate δˆ1 remains unchanged. One can find prior
values δˆβ1  δ2 such that A1 is never selected, because the point estimate δˆ2 would not go
below δˆβ1 . Consequently, the selection would get stuck at the suboptimal arm regardless
of further outcomes. So, the number of patients on both arms does not tend to infinity
as N →∞.
For 1
2
< κ < 1, let Nkj be the indicator function such that
Nj(t) =
{
1 with probability P(δ˜(κ)j (t) = mini δ˜
(κ)
i (t))
0 with probability 1− P(δ˜(κ)j (t) = mini δ˜(κ)i (t))
where δ˜
(κ)
j (t) is a random variable corresponding to the posterior density function after
t observations in the experiment. Let nj(t) =
∑t
i=1Nj(i) be the number of observations
on arm j up to the moment t. We then obtain
E(nj(t)) =
t∑
u=1
ENj(u) =
t∑
u=1
P(δ˜(κ)j (u) = min
i
δ˜
(κ)
i (u)).
Note, that P(δ˜(κ)j (u) = mini δ˜
(κ)
i (u)) has already been studied in (a). The mean of δ˜
(κ)
j (u)
associated with an arm Aj to be selected is an increasing polynomial with respect to N .
The probability to be the minimum decreases for j and increases for i = 1, . . . , j − 1, j +
1, . . . ,m. It follows that the probability of being selected is not a monotonic function and
lim
t→∞
t∑
u=1
P(δ˜(κ)j (u) = min
i
δ˜
(κ)
i (u)) =∞.
The final selection is the arm satisfying (2.9). Consequently, the number of observations
on each arm tends to infinity and we obtain that limN→∞AN = 1 using the arguments
of (a).
B Parameters calibration for the Phase I clinical trial
B.1 Operational prior
A prior for treatment dj can be specified through the mode of the prior distribution,
pˆβj =
νj
βj
. To guarantee the procedure to start from d1 we set pˆβ1 = γ. As an investigator
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has the same amount of knowledge about each treatment we set β1 = . . . = β7 = β. Larger
values of β and the rate of increase correspond to the more conservative escalation scheme
as an investigator needs more observations on each particular treatment to escalate.
Similarly, a greater differences in prior toxicity probabilities would correspond to the
more conservative scheme as well, because it would require more evidence to escalate.
Therefore, one can expect a set prior parameters that would lead to a similar PCS.
The investigation of these parameter influence on the operational characteristics of the
proposed approach is given below.
We consider six different scenarios with different location of the target (Figure 3). For
simplicity, we would assume a priori that toxicity increases linearly between treatments.
Given m = 7, we set the difference between prior toxicities on the d1 and d7 and, then,
interpolate the linear curve for the rest. We would define step = pˆβ7 − pˆβ1 . Then, we
vary values of step and β for each scenarios. The PCS for different combination of step
and β is given in the Figure 3.
Figure 3: The PCS for the WE design using N = 20 and different combinations of β
(vertical axis) and step (horizontal axis). Results are based on 106 simulations.
Brighter colours correspond to higher values of the PCS. A conservative prior (top
right corner on the grid) prevents the WE design from the correct recommendation in
upper line graphs scenarios as higher doses can be hardly reached with N = 20. At the
same time, it leads to an accurate selection in scenarios with highly toxic doses (lower
line scenarios). In contrast, less conservative prior results in higher proportion of correct
recommendation in upper line scenarios and worse in lower line ones. Therefore, there
is a trade-off between the ability to investigate higher doses and the desire to prevent
the high number of toxic responses. Therefore, the geometric mean of the PCS over all
scenarios is chosen as the criterion for the operational prior choice. The geometric mean
for different set of parameters is given in the Figure 4.
There is a set of the prior parameter that lead to the same geometric mean of the
25
0.1 0.2 0.3 0.4 0.5
0.
5
1.
0
1.
5
2.
0
Step
Be
ta
0
5
10
15
20
25
30
35
Figure 4: The geometric mean of the proportion of correct recommendations by the
proposed WE method using different set of prior parameters: β (vertical axis) and the
difference between the risk of toxicity on the lowest and highest dose (horizontal axis) in
six scenarios: with the TD at the bottom, in the middle and at the top of the investigated
dose range. 106 simulations are used.
PCS across all scenarios. We choose a prior that carries limited information β = 1 and
fix the rate to maximize the geometric mean among all scenarios. Thus, the following
vector of modes pˆ is chosen
pˆ = [0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55]T.
We also consider the case of N = 25 thought the same set of scenarios to illustrate the
influence of the prior parameter for a larger sample size (Figure 5). There is a a similar
dependence pattern on β and step. However, the set of the equivalent operational prior
parameters is now wider that means the importance of the prior distribution decreases
with the sample size as one would expect.
B.2 Safety constraint
Parameters r and γ∗ determine the strictness of the safety constraint. Greater values of
r and smaller values of γ∗ would lead to more conservative escalation. It helps to avoid
high risk in unsafe scenarios, but also to prevent the correct recommendation in flat safe
scenarios. There is a clear trade-off in the choice of these parameters that is precisely
studied below.
Let us consider two extreme scenarios: a linear flat dose response shape with the
target treatment far from the bottom (d5) and the scenario with no safe treatment at
all. The operating characteristics of the proposed method in these two scenarios with
different parameters of the safety constraint γ∗ and r are given in Table 6.
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Figure 5: The geometric mean of the proportion of correct recommendations by the
proposed WE method using different set of prior parameters: β (vertical axis) and the
difference between the risk of toxicity on the lowest and highest dose (horizontal axis) in
six scenarios. Total sample size N = 25. 106 simulations are used.
Table 6: The operating characteristics of the proposed design in a linear and an unsafe
scenario for different parameters of the safety constraint. The figures in the upper line
of each cell corresponds to termination proportion in the unsafe scenario. The lower cell
entries corresponds to the PCS in the flat linear scenario. The bold figures correspond to
γ∗ = 0.45 and r = 0.035 which were used in simulations. Results based on 106 replications.
r
0.010 0.015 0.020 0.025 0.030 0.035 0.040 0.045
γ∗ = 0.55
0.00 0.32 4.32 18.47 36.15 49.06 61.49 75.70
26.47 26.65 26.40 26.05 26.85 25.03 24.10 20.23
γ∗ = 0.50
0.15 2.50 17.76 38.75 52.74 63.06 74.94 87.22
26.27 26.22 26.53 27.24 25.46 23.30 20.35 17.10
γ∗ = 0.45
1.13 12.72 35.72 56.49 67.16 77.55 86.53 93.49
26.15 26.02 26.81 25.18 24.26 23.15 18.16 11.05
γ∗ = 0.40
7.47 37.95 59.49 70.52 80.53 88.32 94.18 97.63
26.04 25.91 24.90 21.98 17.66 17.47 11.05 3.51
γ∗ = 0.35
33.98 58.22 74.42 84.14 90.52 94.86 97.90 99.20
25.65 24.54 20.45 15.55 13.77 9.21 6.25 0.70
γ∗ = 0.30
55.51 77.02 87.21 92.99 96.50 98.55 99.37 99.83
24.21 18.09 14.40 11.42 7.13 0.95 0.08 0.04
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The upper line in each cell corresponds to the proportion of times the proposed method
declares that there is no safe dose when there is actually no safe dose. The lower line
corresponds to the proportion of trials the actual TD25 was recommended in a linear
scenario. The most relaxed safety constraint corresponds to the left upper corner. In this
case no trials are terminated in a highly toxic scenario and the proportion of times the
TD25 is recommended in the linear scenario is high. The right lower corner corresponds
to the strictest safety constraint. In this case near all trials will be terminated when
there is no safe dose, but the method will often not find the TD25 in the linear scenario.
Therefore, the trade-off is to sacrifice the accuracy of the method when the TD25 is far
from the bottom in order to prevent the recommendation of highly toxic dose in unsafe
scenario.
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